Dear Shareholders,
I am happy to present the annual report for the year 2023-2024, a year that would go
down as a year of consolidation & consistency in the history of GlobalSpace.
This financial year, our revenue has grown by more than 65% & we continue to
consolidate our Health & Pharma Tech play. Our flagship platforms DocExa & MediOla
contributed more than 90% to our current year's revenues which is in sink with our
expectations. We continue to invest in R&D to further strengthen both platforms to
evolve into one of the most innovative and technologically advanced ecosystems. Our
digital therapeutics play with GoRoga soft launch in Jan got great response from some
leading Psychiatrists of India. We are quite confident that with GoRoga, we would be able
to help Millions for their mental wellness
I am happy to share that this FY we did a strategic acquisition in the form of
Innopharm healthcare Pvt Ltd. This marks a significant step forward in our growth strategy
aligned with our vision for the pharma industry. InnoPharm is a distinguished contract
sales force organization with marquee pharmaceutical companies as clients. This strategic
move marks a significant milestone for both companies, bringing together their
complementary strengths, to create a powerhouse of integrated solutions.
In next two to three years, we hope to attain a significant thought leadership position
in digital health & pharma tech space with truly integrated platform for all
stakeholders of the ecosystem. We firmly believe that next 2 years would definitely be the
value discovery years for your company
I would like to further state that our commitment to all our esteemed shareholders is
that we would continue our journey with clear intent, razor sharp focus & absolute
commitment to build India's most innovative Health & Pharma tech company in next 3
years
Looking forward to all of yours trust, support & best wishes.
SD/-
Krishna Singh
Chairman